LONDON: DeepMatter Group, company focusing on digitising chemistry, has signed a contract with the Cancer Research UK Beatson Institute and Cancer Research Technology (the commercialisation and development arm of Cancer Research UK) for its DigitalGlassware platform.
The technology will be installed within the institute’s Drug Discovery Unit to enable the accurate and reproducible sharing of its research output with its outsourced chemistry partners located in China.
The use of DigitalGlassware™ means the Drug Discovery Unit will be able to share its cutting-edge chemistry across locations, so that work is not needlessly duplicated nor time and money wasted, and ultimately so new discoveries might be made faster.
The DigitalGlassware platform will allow the Drug Discovery Unit to accurately and systematically record, code and enter the results of their experiments into a shared data cloud, enabling the sharing of details of their experiments from anywhere and in real-time.
A subsequent deployment in China is anticipated to take place later in 2020.
Mark Warne, CEO of DeepMatter Group, commented: “We are very proud to be working with Cancer Research UK Beatson Institute, one of Europe’s leading cancer research centres, and delighted that through the use of our technology, DeepMatter is able to support them in their life-saving work.
“The difficulty in consistently reproducing quality chemistry globally is an issue that continues to plague chemists. DigitalGlassware addresses this problem and we believe it has the potential to transform the industry.”
Justin Bower, Joint Head of the Drug Discovery Unit and Head of Chemistry at the Cancer Research UK Beatson Institute, added: “We know that improved reproducibility in our work, particularly when achieved across multiple sites, will lead to enhanced productivity and a faster speed of discovery. DeepMatter’s technology is some of the most innovative we have seen to date and we look forward to working with them test its capabilities.”